Systemic Anti Cancer Therapy Protocols

These clinical protocols have been developed by local clinicians, with the support of the South West Clinical Network (SWCN). The information is provided as guidance only, and has no legal or official standing. The guidance does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and/or their guardian or carer. Availability of treatments may change, subject to NHS funding agreements. These protocols must be used in conjunction with local and national commissioning guidance.

The protocols are still being updated and more will be added to this website as they are completed. If you have any queries or suggestions, or would like to be involved in the development of these protocols please contact us

Bendamustine, Thalidomide and Dexamethasone (BTD)

Haematology

Ruxolitinib

Myeloproliferative disorders

Haematology

Hydroxycarbamide

Myeloproliferative disorders

Haematology

Busulphan

Myeloproliferative disorders

Haematology

Azacitidine

Myeloproliferative disorders

Haematology

Cladribine

Hairy Cell Leukaemia

Haematology

Ponatinib

Chronic Myeloid Leukaemia

Haematology

Nilotinib

Chronic Myeloid Leukaemia

Haematology

Imatinib

Chronic Myeloid Leukaemia

Haematology

Hydroxycarbamide

Chronic Myeloid Leukaemia

Haematology

Dasatinib

Chronic Myeloid Leukaemia

Haematology

Bosutinib

Chronic Myeloid Leukaemia

Haematology

Search by filter

  • Haematology/Oncology

  • Location

  • Protocol Area